American Diabetes Association
Browse
PRESENTATION
Supplemental_Figure_1.pptx (363.9 kB)
PRESENTATION
Supplemental_Figure_2.pptx (7.23 MB)
PRESENTATION
Supplemental_Figure_3.pptx (2.19 MB)
DOCUMENT
Suppl._Table_1_(qRT-PCR_Primers).pdf (129.99 kB)
DOCUMENT
Suppl._Table_2_(Differential_expression_at_ZT_4_in_Bmal1OV_(HFD)_vs._Control_(HFD))_R2.pdf (547.05 kB)
DOCUMENT
Suppl._Table_3_(Differential_expression_at_ZT_16_in_Bmal1OV_(HFD)_vs._Control_(HFD))_R2.pdf (360.82 kB)
DOCUMENT
Suppl._Table_4_(Pathway_analysis_at_ZT_4_in_Bmal1OV_(HFD)_vs._Control_(HFD))_R2.pdf (65.56 kB)
DOCUMENT
Suppl._Table_5_(Pathway_analysis_at_ZT_16_in_Bmal1OV_(HFD)_vs._Control_(HFD))_R2.pdf (67.33 kB)
DOCUMENT
Human_Islet_Checklist_(Bmal1_OV)_R1.pdf (119.25 kB)
1/0
9 files

Induction of core circadian clock transcription factor Bmal1 enhances β cell function and protects against obesity-induced glucose intolerance

figure
posted on 2020-10-21, 17:45 authored by Ada AdminAda Admin, Kuntol Rakshit, Aleksey V. Matveyenko
Type 2 diabetes mellitus (T2DM) is characterized by β cell dysfunction due to impaired glucose-stimulated insulin secretion (GSIS). Studies show that β cell circadian clocks are important regulators of GSIS and glucose homeostasis. These observations raise the question whether enhancement of the circadian clock in β cells will confer protection against β cell dysfunction under diabetogenic conditions. To test this we employed an approach by first generating mice with β cell-specific inducible overexpression of Bmal1 (core circadian transcription factor; β-Bmal1OV). We subsequently examined the effects of β-Bmal1OV on the circadian clock, GSIS, islet transcriptome, and glucose metabolism in context of diet-induced obesity. We additionally tested the effects of circadian clock-enhancing small molecule Nobiletin on GSIS in mouse and human control and T2DM islets. We report that β-Bmal1OV mice display enhanced islet circadian clock amplitude, augmented in vivo and in vitro GSIS and are protected against obesity-induced glucose intolerance. These effects were associated with increased expression of purported BMAL1-target genes mediating insulin secretion, processing, and lipid metabolism. Furthermore, exposure of isolated islets to Nobiletin enhanced β cell secretory function in Bmal1-dependent manner. This work suggests therapeutic targeting of the circadian system as a potential strategy to counteract β cell failure under diabetogenic conditions.

Funding

We acknowledge funding support from the National Institutes of Health (2R01DK098468 to AVM) and the Center for Regenerative Medicine (Mayo Clinic, Rochester, MN).

History

Usage metrics

    Diabetes

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC